TKTL-1 expression in lung cancer

Pathology Research and Practice

Volumn 208, Issue 4, 2012, Pages 203-209

  Fritz, Peter ^a,b   Coy, Johannes F ^c   Mürdter, Thomas E ^d   Ott, German ^b   Alscher, Mark Dominik ^a,e   Friedel, Godehard ^e  

^a ROBERT BOSCH HOSPITAL   (Germany)

^b Institut für Digitale Medizin Stuttgart San Franzisco   (United States)

^c Darmstadt and Tavargenix GmbH   (Germany)

^d DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^e Klinik Schillerhohe   (Germany)

Author keywords

Aerobic glycolysis; Biomarker; Glucose metabolism; Ketogenic diet; Lung cancer; Pentose phosphate pathway (PPP); Pharmacodiagnostic marker; Transketolase (TKT); Transketolase like 1 (TKTL1); Warburg effect

Indexed keywords

TRANSFERASE; TRANSKETOLASE LIKE PROTEIN 1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENDER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROTEIN EXPRESSION; SMOKING;

EID: 84859444873     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2012.01.007     Document Type: Article

References (41)

1. Bartlett J.M., Brookes C.L., van de Velde T., Robson C.J., Billingham L.J., Campbell F.M., Grant M., Hasenburg A., Hille E.T., Kay C., Kieback D.G., Putter H., Markopoulos C., Kranenbarg E.M., Mallon E.A., Dirix L., Ceynaeve C., Rea D. Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospective powered pathology study in the tamoxifen exemestane adjuvant multinational trial. Clin. Oncol. 2011, 20:1531-1538.
2. Birim O., Kappetein A.P., Waleboer M., Puvimanasinghe J.P., Eijkkemans M.J., Steyerberg E.W., Versteegh M.I., Bogers A.J. Long-term survival after non-small cell lung cancer surgery: development and validation of a prognostic model with a preoperative and postoperative mode. J. Thorac. Cardiovasc. Surg. 2006, 132:491-498.
3. Bentz S., Pesch T., Wolfram L., de Valliere C., Leucht K., Fried M., Coy J.F., Hausmann M., Rogler G. Lack of transketolase-like (TKTL) aggravates murine experimental colitis. Am. J. Physiol. 2011, 300:598-607.
4. Boros L.G., Lapis K., Szende B., Tömösközi-Farkas R., Balogh A., Boren J., Marin S., Cascante M., Hidvégi M. Wheat germ extract decreases glucose uptake and RNA ribose formation but increases fatty acid synthesis in MIA pancreatic adenocarinoma cells. Pancreas 2001, 23:141-147.
5. Buzzai M., Bauer D.E., Jones R.G., Deberardinis R.J., Hatzivassiliou G., Elstrom R.L., Thompson C.B. The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid beta-oxidation. Oncogene 2005, 24:4165-4173.
6. Cascantes M., Centelles J.J., Veech R.L., Lee W.N., Boros L.G. Role of thiamin (vitamin B1) and transketolase in tumor cell proliferation. Nutr. Cancer 2000, 36:150-154.
7. Chen H., Yue J.X., Yang S.H., Ding H., Zhao R.W., Zhang S. Overexpresskion of transketolase-like gene 1 is associated with cell proliferation in uterine cervix cancer. J. Exp. Clin. Cancer Res. 2009, 28:43.
8. Comin-Anduix B., Boren J., Martinez S., Moro C., Centiles J.J., Trebukhina R., Petuschok N., Lee W.N., Boros L.G., Cascante M. The effect of thiamine supplementation on tumor proliferation. A metabolic control analysis study. Eur. J. Biochem. 2001, 268:4177-4182.
9. Comín-Anduix B., Boren J., Martinez S., Moro C., Centelles J.J., Trebukhina R., Petushok N., Lee W.N., Boros L.G., Cascante M. The effect of thiamine supplementation on tumor proliferation. A metabolic control analysis study. Eur. J. Biochem. 2001, 268:4177-4182.
10. Coy J.F., Dressler D., Wilde J., Schubert P. Mutations in the transketolase-like gene TKTL1: clinical implications for neurodegenerative diseases, diabetes and cancer. Clin. Lab. 2005, 51:257-273.
11. Coy J.F., Dübel S., Kioschis P., Thomas K., Micklem G., Delius H., Poustka A. Molecular cloning of tissue-specific transcripts of a transketolase-related gene: implications for the evolution of new vertebrate genes. Genomics 1996, 32:309-316.
12. Dihal A.A., van der Woude H., Hendriksen P.J., Charif H., Dekker L.J., Ijsselstijn L., de Boer V.C., Alink G.M., Burgers P.C., Rietjens I.M., Woutersen R.A., Stierum R.H. Transcriptome and proteome profiling of colon mucosa from quercetin fed F344 rats point to tumor preventive mechanisms, increased mitochondrial fatty acid degradation and decreased glycolysis. Proteomics 2008, 8:45-46.
13. Elstrom R.L., Bauer D.E., Buzzai M., Karnauskas R., Harris M.H., Plas D.R., Zhuang H., Cinalli R.M., Alavi A., Rudin C.M., Thompson C.B. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res. 2004, 64:3892-3899.
14. Garber K. Energy deregulation: licensing tumors to grow. Science 2006, 312:1158-1159.
15. Giaccone G., Herbst R.S., Manegold C., Scagliotti G., Rosell R., Miller V., Natale B.B., Schiller J.H., Von Pawel J., Pluzanska A., Gatzemeier U., Grous J., Ochs J.S., Averbuch S.D., Wolf M.K., Rennie P., Fandi A., Johnson D.H. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J. Clin. Oncol. 2004, 22:777-784.
16. Herbst R.S., Giaccone G., Schiller J.H., Natale R.B., Miller V., Manegold C., Scagliotti G., Rosell R., Oliff I., Reeves J.A., Wolf M.K., Krebs A.D., Averbuch S.D., Ochs J.S., Grous J., Fandi A., Johnson D.H. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J. Clin. Oncol. 2004, 22:785-794.
17. Hortobagyi G.N., Sauter G. Challenges and opportunities for Erlotinib (Tarceva): what does the future hold?. Semin. Oncol. 2003, 7(Suppl.):3047-3053.
18. Ihrlund L.S., Hernlund E., Khan O., Shoshan M.C. Bromopyruvate as inhibitor of tumor cell energy metabolism and chemopotentiator of platinum drugs. Mol. Oncol. 2008, 2:94-101.
19. Jemal R., Siegel E., Ward T., Murray T., Xu J., Smigal C., Thun M.J. Cancer statistics. CA Cancer J. Clin. 2006, 56:106-130.
20. Kayser G., Kassem A., Sienel W., Schulte-Uentrop L., Mattern D., Aumann K., Stickeler E., Werner M., Passlick B., zur Hausen A. Lactate-dehydrogenase 5 is overexpressed in non-small cell lung cancer and correlates with the expression of the transketolase-like protein. Diagn. Pathol. 2010, 12:22.
21. Kelloff G.J., Hoffman J.M., Johnson B., Scher H.I., Siegel B.A., Cheng E.Y., Cheson B.D., O'Shaughnessy J., Guyton K.Z., Mankoff D.A., Shankar L., Larson S.M., Sigman C.C., Schilsky R.L., Sullivan D.C. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin. Cancer Res. 2005, 11:2785-2808.
22. Klenk S., Dippon J., Fritz P., Heidemann G. Interactive survival analysis with the OCDM system: from development to application. Inform. Syst. Front. 2009, 11:293-403.
23. Langbein S., Zerilli M., zur Hausen A., Staiger W., Rensch-Boschert K., Lukan N., Popa J.J., Ternullo M.P., Steidler A.M., Weiss C., Grobholz R., Willekte F., Alken P., Stassi G., Schubert P., Coy J.F. Expression of transketolase: TKTL1 predicts colon and urothelial cancer survival: Warburg effect reinterpreted. Br. J. Cancer 2006, 94:578-585.
24. Natali P.G., Nicotra M.R., Bigotti A., Venturo I., Slamon D.J., Fendly B.M., Ullrich A. Expression of the p 185 encoded by HER2 oncogene in normal and transformed human tissues. Int. J. Cancer 1990, 15:457-461.
25. Nebeling L.C., Lerner E. Implementing a ketogenic diet based on medium-chain triglyceride oil in pediatirc patients with cancer. J. Am. Diet. Assoc. 1995, 95:693-697.
26. Onkologischer Schwerpunkt Stuttgart (OSP). http://www.osp-stuttgart.de/osp/Kontakt.htm.
27. Otto C., Kammerer U., Illert B., Muehling B., Pfetzer N., Wittig R., Voelker H.U., Thiede A., Coy J. Growth of human gastric cancer cells in nude mice is delayed by a ketogenic diet supplemented with omega-3 fatty acids and medium-chain triglycerides. BMC Cancer 2008, 8:122-137. http://wwwbiomedcentral.com/1471-2407/8/122.
28. Paez J.G., Jänne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., Herman P., Kaye F.J., Lindeman N., Boggon T.J., Naoki K., Sasaki H., Fujii Y., Eck J.M., Sellers W.R., Johnson B.E., Meyerson M. EGFR Mutiations in lung cancer: Correlation with clinical response to gefitinib. Science 2004, 304:1497-1500.
29. Pegram M., Slamon D. Biological rationale for HER2/neu(cerbB2) as a target for monoclonal antibody therapy. Semin. Oncol. 2000, 27:13-19.
30. Rais B., Comin B., Puigjaner J., Brandes J.L., Creppy E., Saboureau D., Ennamany R., Lee W.N., Boros L.G., Cascante M. Oxythiamine and dehydroepiandrosterone induce a G1 phase cycle arrest in Ehrlich's tumor cells through inhibition of the pentose cycle. FEBS Lett. 1999, 456:113-118.
31. Sakurai H., Asamura H., Goya T., Eguchi K., Nakanishi Y., Sawabata N., Okumara M., Miaoka E., Fujii Y. Survival differences by gender for resected non-small cell lung cancer: a retrospective analysis of 12,509 cases in a Japanese lung cancer registry. J. Thorac. Surg. 2010, 10:1594-1601.
32. Schultz H., Kähler D., Branscheid D., Vollmer E., Zabel P., Goldmann T. TKTL1 is overexpressed in a portion of non-small cell lung cancer specimens. Diagn. Pathol. 2008, 12:35.
33. Seyfried T.N., Mukherjee P. Targeting energy metabolism in brain cancer: review and hypothesis. Nutr. Metab. 2005, 21(2):30.
34. Shibata A., Nakagawa K., Sookwong P., Tsuduki T., Tomita S., Shirakawa H., Komai M., Miayzawa T. Tocotrienol inhibits secretion of angiogenic factors from human colorectal adenocarcinoma by suppressing hypoxia-inducible factor-1aolpha. J. Nutr. 2008, 138:2136-2142.
35. Simopoulos A.P. The Mediterranean diets: what is so special about the diet of Greece? The scientific evidence. J. Nutr. 2001, 131:3065S-3073S.
36. Staiger W.I., Coy J.F., Grobholz R., Hofheinz R.D., Lukan N., Post S., Schwarzbach M.H., Willecke F. Expression of the mutated TKTL1, a molecular marker in gastric cancer. Oncol. Rep. 2006, 16:657-661.
37. Statistisches Bundesamt Deutschland. http://www.destatis.de/.../Bevoelkerung.psml.
38. Sun W., Liu Y., Glazer C.A., Shao C., Bhan S., Demokan S., Zhao M., Rudek M.A., Ha P.K., Califano J.A. TKTL1 is activated by promoter hypomethylation and contributes to head and neck squamous cell carcinoma carcinogenesis through increased aerobic glycolysis and HIF1alpha stabilization. Clin. Cancer Res. 2010, 16:857-866.
39. Warburg O., Posener K., Negelein E.L. über den Stoffwechsel der Carcinomzelle. Biochem. Z. 1924, 124:309-344.
40. Xu X., Zur Hausen A., Coy J.F., Löchelt M. Transketolase-like protein 1 (TKTL1) is required for rapid cell growth and full viability of human tumor cells. Int. J. Cancer 2009, 124:1330-1337.
41. Zhou M., Zhao Y., Ding V., Liu H., Liu Z., Fodstad O., Riker A.J., Kamerajugadda S., lu J., Owen L.B., Ledoux S.P., Tan M. Warburg effect in chemosensitivity: targeting lactate dehydrogenase-A resensitizes taxol-resistant cancer cells to taxol. Mol. Cancer 2010, 9:33.